The current limitations on the use of immunotherapy drugs could be swept away thanks to the development of immune checkpoint inhibitors. They block disruptive proteins that limit the body’s natural immune response and stop T-Cells from destroying cancer cells. Some of the biggest factors stopping the more widespread use of these drugs are the limitations of current standards in effectively measuring how well they work. Read how improvements in the methods used for immuno-oncology drug trials could benefit both researchers and patients.
A Sponsor was facing difficulties with tracking payment details, critical for financial transparency and requirement details. Read how eClinicalGPS played an integral role in their mission to modernize clinical investigator payment processes.
For this biotech, the big challenge was both a lack of expertise and resources needed to manage registration of trials and posting results.TrialScope provided a proven solution that optimizes the e ciency of disclosure activities,
maximizes trial data transparency, and fosters more informed, engaged patients through open research sharing.
Web-based survey tools can be extremely beneficial to pharmaceutical companies and CROs for reducing site selection cycle time as well as operational costs (not to mention the opportunity costs). But what sets site feasibility, and other clinical forms, apart from other nonclinical survey types?
Unsure if a REMS is needed during product development? This article will answer that question and give guidance if implementing a REMS is necessary.
It is difficult to quantify the soft costs of managing a clinical trial. One factor guilty of contributing to spiraling soft costs is time. Download Almac’s case study that demonstrates how Almac’s One Clinical Trial Supply Solution helped a pharmaceutical company streamline its clinical trial operations, resulting in time and cost savings.
As companies are looking to reduce their supplier base and shifting towards more strategic relationships with key suppliers to achieve economies of scale, learn how contract suppliers can benefit from developing strategic partnerships with other vendors and operating as one entity.
Dr. Joan Meyer, Covance Executive Director of Strategy & Planning for Inflammation, Infectious Diseases and General Medicine, discusses her team’s efforts to better understand patients’ opinions about inflammatory bowel disease trials and develop patient-centered clinical strategies to improve study recruitment.
A large pharmaceutical company asked Covance to support their studies for a diabetes Phase III program specifically to register a drug to treat Type 2 Diabetes. Read how Covance utilized its rich central laboratory services database and helped the sponsor achieve first patient in (FPI) ahead of schedule for all studies in the program and beat historical industry performance across a number of key metrics.
An emerging biopharmaceutical company was designing a Phase II trial in patients who had Type 2 Diabetes, Stage 3 chronic kidney disease (CKD) and macroalbuminuria. They were uncertain about how to balance the selection of the right patients for their trial endpoints with the ability to achieve rapid subject recruitment. Read how LabCorp de-identified clinical laboratory data helped evaluate the protocol feasibility and the overall design of the study while also making an adjustment in eligibility criteria was forecast to double the eligible patient pool – without impacting study endpoints.
|
|
|
|
|
|
|
|
|